319 related articles for article (PubMed ID: 37069029)
1. Adaptive Immunity in Genitourinary Cancers.
Koti M; Bivalacqua T; Black PC; Cathomen T; Galsky MD; Gulley JL; Ingersoll MA; Kamat AM; Kassouf W; Siemens DR; Gao J
Eur Urol Oncol; 2023 Jun; 6(3):263-272. PubMed ID: 37069029
[TBL] [Abstract][Full Text] [Related]
2. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapies in GU malignancies.
Drakaki A; McDermott DF
Curr Oncol Rep; 2013 Jun; 15(3):224-31. PubMed ID: 23519772
[TBL] [Abstract][Full Text] [Related]
7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
Marciscano AE; Madan RA
Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
[TBL] [Abstract][Full Text] [Related]
9. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
10. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
[TBL] [Abstract][Full Text] [Related]
13. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
14. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
15. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
Dallos MC; Drake CG
Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
[TBL] [Abstract][Full Text] [Related]
16. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer.
Hamade A; Li D; Tyryshkin K; Xu M; Conseil G; Yolmo P; Hamilton J; Chenard S; Robert Siemens D; Koti M
Biol Sex Differ; 2022 May; 13(1):19. PubMed ID: 35505436
[TBL] [Abstract][Full Text] [Related]
18. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
19. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in genitourinary malignancies.
Wattenberg MM; Fong L; Madan RA; Gulley JL
Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
